Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40 % of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly pembrolizumab, has changed the adjuvant treatment landscape. The Tuscan Interdisciplinary Uro-Oncological Group (GIOTTO) provides practical guidance on patient selection and clinical use of adjuvant pembrolizumab in RCC.
Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group / Roviello, Giandomenico; Paolieri, Federico; Catalano, Martina; Galli, Luca; Doni, Laura; Peschiera, Federico; Pili, Alessandro; Sisani, Michele; Francesco, Bloise. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 216:(2025), pp. 104978.1-104978.6. [10.1016/j.critrevonc.2025.104978]
Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group
Roviello, Giandomenico;Catalano, Martina
;Peschiera, Federico;Pili, Alessandro;
2025
Abstract
Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40 % of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly pembrolizumab, has changed the adjuvant treatment landscape. The Tuscan Interdisciplinary Uro-Oncological Group (GIOTTO) provides practical guidance on patient selection and clinical use of adjuvant pembrolizumab in RCC.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Roviello et al., Crit Rev Oncol Hematol, 2025.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
589.6 kB
Formato
Adobe PDF
|
589.6 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
